No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

PharmaCountry

Home

No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

PharmaCountry

Research & Reports | Pharmacountry Insights

Home/Insights/Research & Reports

Research & Reports

Whitepapers, research reports and market data

#Cetirizine ×

Daily News Market Analysis Research & Reports Regulatory Updates

Research & Reports

Sep 14, 2026•

3 min read

Korean Prime Pharma Initiates Phase 1 Trial of Cetirizine ODT (KPP-2603-T)

Korean Prime Pharma received approval to start a Phase‑1 exploratory study of its cetirizine orally disintegrating tablet (KPP‑2603‑T) in six healthy adults.